Multigene methylation analysis of conventional renal cell carcinoma

Urologia Internationalis

Volumn 83, Issue 1, 2009, Pages 107-112

  Onay, H ^a   Pehlivan, S ^b   Koyuncuoglu, M ^c   Kirkali, Z ^c   Ozkinay, F ^a  

^a EGE UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Methylation; Renal cell carcinoma

Indexed keywords

DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; EARLY DIAGNOSIS; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; NEPHRECTOMY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCREENING TEST;

ADULT; AGED; CARCINOMA, RENAL CELL; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 68549090872     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224878     Document Type: Article

References (25)

1. Kirkali Z, Lekili M: Renal cell carcinoma: new prognostic factors? Curr Opin Urol 2003;13:433-438.
2. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-1623.
3. Drucker BJ: Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005;31:536-545.
4. Battagli C, Uzzo RG, Dulaimi E, Ibanez de Caceres I, Krassenstein R, Al-Saleem T, et al: Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res 2003;63:8695-8699.
5. Campbell SC, Flanigan RC, Clark JI: Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol 2003;4:363-372.
6. Hoque MO, Begum S, Topaloglu O, Jeronimo C, Mambo E, Westra WH, et al: Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-5517.
7. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
8. Dulaimi E, Ibanez de Caceres I, Uzzo RG, Al-Saleem T, Greenberg RE, Polascik TJ, et al: Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004;10:3972-3979.
9. http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?db=gene&cmd= Retrieve&dopt=full-report&list-uids=11186
10. Baylin SB, Belinsky SA, Herman JG: Aberrant methylation of gene promoters in cancer concepts, misconcepts, and promise. J Nat l Cancer Inst 2000;92:1460-1461.
11. Ahonen M, Baker AH, Kahari VM: Adeno-virus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998;58:2310-2315.
12. http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?cmd=Search&db= OMIM&term=175100&doptcmdl=Detailed&tool=genome.ucsc. edu#175100-MOLECULAR-GENETICS
13. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J, Karran P: Epigenetic regulation of the MGMT and hMSH6DNA repair genes in cells resistant to methylating agents. Cancer Res 2000;60:3262-3270.
14. Sanz-Casla MT, Maestro ML, del Barco V, Zanna I, Moreno J, Vidaurreta M, et al: Loss of heterozygosity and methylation of p16in renal cell carcinoma. Urol Res 2003;31:159-162.
15. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, et al: Aberrant promoter methylation profile of prostate cancers and its relationship to clini-copathological features. Clin Cancer Res 2002;8:514-519.
16. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
17. Yorukoglu K, Aktas S, Mungan MU: Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma. Urology 1999;53:684-689.
18. Ljungberg B, Alamdari FI, Stenling R, Roos G: Prognostic significance of the Heidelberg classification of renal cell carcinoma. Eur Urol 1999;36:565-569.
19. Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Ca ncer Res 2001;61:3225-3229.
20. Nojima D, Nakajima K, Li LC, Franks J, Ribeiro-Filho L, Ishii N, Dahiya R: CpG methylation of promoter region inactivates E-cadherin gene in renal cell carcinoma. Mol Carcinog 2001;32:19-27.
21. Kawakami T, Okamoto K, Kataoka A, Koizumi S, Iwaki H, Sugihara H, et al: Multipoint methylation analysis indicates a distinctive epigenetic phenotype among testicular germ cell tumors and testicular malignant lymphomas. Genes Chromosomes Cancer 2003;38:97-101.
22. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al: Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-4371.
23. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, et al: Promoter methylation and silencing of the reti-noic acid receptor-be ta gene in lung carcinomas. J Natl Cancer Inst 2000;92:1303-1307.
24. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, et al: Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 2003;22:6794-6801.
25. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, et al: Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999;59:798-802.